Serologic evidence of Toxoplasma gondii infection among cancer patients

References

1. ↵
   1. Imam A,
   2. Al-Anzi FG,
   3. Al-Ghasham MA,
   4. Al-Suraikh MA,
   5. Al-Yahya AO,
   6. Rasheed Z

   (2017) Serologic evidence of Toxoplasma gondii infection among cancer patients. A prospective study from Qassim region, Saudi Arabia. Saudi Med J 38:319–321.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Machala L,
   2. Kodym P,
   3. Malý M,
   4. Geleneky M,
   5. Beran O,
   6. Jilich D

   (2015) Toxoplasmosis in immunocompromised patients. Epidemiol Mikrobiol Imunol 64:59–65.

   OpenUrl
3. ↵
   1. Jiang C,
   2. Li Z,
   3. Chen P,
   4. Chen L

   (2015) The Seroprevalence of Toxoplasma gondii in Chinese Population With Cancer: A Systematic Review and Meta-analysis. Medicine (Baltimore) 94:e2274.

   OpenUrlCrossRefPubMed
4. ↵
   1. Lappalainen M,
   2. Hedman K

   (2004) Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity. Ann Ist Super Sanita 40:81–88.

   OpenUrlPubMed
5. ↵
   1. Seyedeh MS,
   2. Nahid S,
   3. Nahid M,
   4. Shima DP,
   5. Morteza Y,
   6. Hossein YD

   (2015) Low titer of antibody against Toxoplasma gondii may be related to resistant to cancer. J Cancer Res Ther 11:305–307.

   OpenUrl
6. ↵
   1. Robert-Gangneux F,
   2. Belaz S

   (2016) Molecular diagnosis of toxoplasmosis in immuno compromised patients. Curr Opin Infect Dis 29:330–339.

   OpenUrlCrossRef